Comments
Strides Pharma Science Limited’s shares were up by 0.67 per cent after the company announced that its subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval from the United States Food & Drug Administration (USFDA) for its Sodium Sulphate, Potassium Sulphate, and Magnesium Sulphate Oral Solution 17.5g/3.13g/1.6g per 6 ounces, a generic version of the Suprep Bowel Prep Kit.
Strides’ portfolio now encompasses both prescription and over-the-counter bowel preparation products. The market size for the approved product is estimated to be approximately US$143 million, according to IQVIA. Manufacturing of the newly approved product will take place at the company’s facility in Bengaluru.
Sodium Sulphate, Potassium Sulphate, and Magnesium Sulphate Oral Solution 17.5g/3.13g/1.6g per 6 ounces belong to a category of medicines prescribed for individuals undergoing a colon cleanse before a colonoscopy. The kit includes two 6-ounce bottles of the liquid and a mixing container.
The shares were up by 0.67 per cent to ₹489.70 at 10 am on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.